Does Wearable ECG Accurately Detect Atrial Fibrillation?

When wearable single-lead ECG readings are compared against a physician-read 12-lead ECG or clinical rhythm monitoring, accuracy is often reported in the low-to-mid 90s and above for both sensitivity and specificity. That accuracy has been demonstrated across multiple device types and study designs, though the same body of research also shows meaningful device-to-device variation and a nontrivial rate of readings the algorithm simply can't classify.

The question people are actually asking

Someone gets a wrist notification flagging an irregular rhythm, or sees a smartwatch ECG readout that says something inconclusive, and the real question underneath isn't abstract. It's whether that reading means anything close to what a cardiologist's ECG would mean, or whether it's closer to a glorified guess dressed up in clinical language.

That question splits into two smaller ones that the research treats separately: how good is the underlying detection algorithm at telling AFib from normal rhythm when it does render a verdict, and how often does it fail to render one at all. Both matter. The evidence below speaks mostly to the first.

In everyday use rather than the lab, a meta-analysis of wearable activity trackers pooled atrial fibrillation detection at 94.2 percent sensitivity and 95.3 percent specificity, with 87.4 percent of positive alerts confirmed (JMIR Mhealth and Uhealth, 2024).

Where the accuracy story gets more complicated

The pooled numbers above look clean, but they come from combining many different devices, algorithms, and patient populations into single summary curves. When researchers instead tested several specific consumer devices side by side against the same reference standard in the same cohort, the results spread out more than the meta-analyses might suggest.

A real-world comparison of five direct-to-consumer smart devices against a physician-read 12-lead ECG found sensitivity ranging from 58% to 85% and specificity from 69% to 79% depending on the device, plus an inconclusive-tracing rate between 17% and 26%. Same detection task, same reference standard, and still a meaningful range in how often each device got it right or simply couldn't decide. Anyone comparing specific models side by side might find a closer look at device-to-device accuracy and inconclusive readings useful for seeing how that variation plays out.

A separate line of research has focused on tightening specificity further, since a false positive on a screening tool triggers unnecessary downstream testing. One approach combining single-lead ECG and PPG algorithms in sequence reported sensitivity of 99.6% and specificity of 97.4% for one algorithm pairing, though the same study noted that one algorithm alone failed to render a diagnosis in 16.1% of cases. The inconclusive-result problem doesn't disappear just because sensitivity climbs.

Against an implanted cardiac monitor in 24 patients over 31,349 hours, an Apple Watch with a KardiaBand and AliveCor’s algorithm caught 80 of 82 atrial fibrillation episodes lasting an hour or more, but only 39.9 percent of the episodes it flagged were real (Circulation. Arrhythmia and Electrophysiology, 2020).

A review of wearable AF devices found ECG patches reached 92 to 98 percent sensitivity and 85 to 97 percent specificity and found more episodes than short Holter recordings, while optical smartwatches showed moderate to high accuracy for irregular pulse, limited by motion, false positives and adherence (Future Cardiology, 2026).

What a positive notification does and doesn't confirm

It matters that the large population-scale studies were built around a two-step design, a wearable flags something, and a separate clinical-grade monitor confirms or refutes it before anyone is told they have AFib. In the smartwatch trial, only a small fraction of participants over the monitoring period ever received an irregular pulse notification in the first place, and confirmation relied on ECG patch data that was often applied many days after the notification. A second large study using a different wearable platform followed the same logic, using a week of ambulatory ECG patch monitoring after an irregular rhythm detection to establish whether AFib was actually present, with positive predictive value of that first detection as the primary outcome.

So a wearable alert is a screening signal, not a diagnosis, and the study design itself seems to admit as much. The accuracy numbers in the evidence block describe how well the algorithm's classification lines up with a confirmed rhythm once that confirmation step happens. Whether acting on that structure changes anything downstream, like stroke risk, is a separate question the accuracy research here doesn't address; that's covered in a separate look at whether wearable AFib screening reduces stroke risk.

In a Chinese screening program using Huawei and Honor watches and bands, 424 of 187,912 people monitored received a suspected-AF notification, and 227 of the 262 who were followed up were confirmed to have atrial fibrillation (Journal of the American College of Cardiology, 2020).

Phone camera apps show why a good test can still produce mostly false alarms. Across 10 studies and 3,852 people they reached 94.2 percent sensitivity and 95.8 percent specificity, yet in people 65 and over without symptoms the modeled share of positive results that were real was only 19.3 to 37.5 percent, while a negative result was right over 99.8 percent of the time (JAMA Network Open, 2020).

Why the detection question keeps coming up

Part of the reason this keeps getting asked is scale. AFib is common and getting more common, with global prevalence estimated in the tens of millions and rising over recent decades, and a substantial share of cases are asymptomatic. People can carry the condition without feeling anything that would send them to a doctor on their own. A device on the wrist that's already being worn for steps and sleep is an appealing way to catch something that might otherwise go unnoticed until a stroke or other complication reveals it.

That backdrop is why the diagnostic accuracy question carries weight beyond curiosity. If wearable detection performs the way the meta-analyses describe, it changes what counts as a plausible first signal of an asymptomatic arrhythmia. The accuracy research answers that narrow question reasonably consistently, but what it doesn't answer, on its own, is what should happen clinically once that signal appears.

Common questions